Jump to content


Interesting Article

  • Please log in to reply
1 reply to this topic

#1 Sneezy12


    Advanced Member

  • Members
  • PipPipPip
  • 67 posts
  • LocationMinnesota

Posted 24 October 2012 - 06:31 PM

http://medicalxpress...nt-chronic.html    Frank

#2 Trey


    Advanced Member

  • PS Beta Group
  • PipPipPip
  • 1,705 posts
  • LocationSan Antonio, Texas

Posted 24 October 2012 - 09:06 PM

It seems premature to combine bosutinib with anything since it has not proven itself against CML.  And especially combining bosutinib with danusertib (a pan-aurora kinase inhibitor) is a bit odd.  The Aurora kinase inhibitors have a questionable history, and some have been abandoned after severe impact on the heart.  I personally think the pan-aurora kinase inhibitors should only be used where there is no other option.  For the gatekeeper mutation (T315i) there is Ponatinib, which should be used first.

1 user(s) are reading this topic

0 members, 1 guests, 0 anonymous users